title: Pegylated liposomal doxorubicin in ovarian cancer.
abstract: Pegylated liposomal doxorubicin is a formulation of doxorubicin in which the molecule itself is packaged in a liposome made of various lipids with an outer coating of polyethylene glycol. Liposomal technology is being used in increasing amounts in the therapy of a variety of cancers, including ovarian cancers. This article reviews the mechanistic actions of this formulation, the Phase II and Phase III data that helped define the role of pegylated liposomal doxorubicin in recurrent ovarian cancer, as well as a discussion of some of the side-effects and their management.
authors: Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic, Cleveland, OH 44195, USA.
authors: Andrew E
authors: AE
authors: Green
authors: Peter G
authors: PG
authors: Rose
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000737:chemistry; D004317:Doxorubicin / Q000008:administration & dosage* / Q000737:chemistry*; D004337:Drug Carriers / Q000737:chemistry*; D005260:Female; D006801:Humans; D008081:Liposomes / Q000737:chemistry*; D050997:Nanomedicine / Q000379:methods*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011092:Polyethylene Glycols / Q000737:chemistry*
chemical_list: D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D008081:Liposomes; D011092:Polyethylene Glycols; D004317:Doxorubicin
references: J Clin Oncol. 1995 Jul;13(7):1777-85
references: 7602367
references: Cancer. 2002 Nov 15;95(10):2223-9
references: 12412177
references: Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:79-85
references: 16515572
references: Cancer. 2003 Aug 1;98(3):610-7
references: 12879480
references: Tumori. 2003 May-Jun;89(3):237-49
references: 12908776
references: Anticancer Res. 2003 Jul-Aug;23(4):3543-8
references: 12926104
references: Gynecol Oncol. 2003 Aug;90(2 Pt 2):S1-7
references: 12927999
references: Ann Oncol. 2003 Sep;14(9):1406-11
references: 12954580
references: Gynecol Oncol. 2003 Sep;90(3):610-8
references: 13678734
references: Anticancer Drugs. 2003 Sep;14(8):633-8
references: 14501385
references: Br J Cancer. 2003 Oct 6;89(7):1180-4
references: 14520442
references: Ann Oncol. 2004 Mar;15(3):440-9
references: 14998846
references: Gynecol Oncol. 2004 Aug;94(2):320-4
references: 15297168
references: Gynecol Oncol. 2004 Aug;94(2):409-15
references: 15297181
references: Gynecol Oncol. 2004 Oct;95(1):1-8
references: 15385103
references: Int J Gynecol Cancer. 2006 Jan-Feb;16(1):65-70
references: 16445612
references: Oncology. 2004;67(3-4):183-6
references: 15557776
references: Gynecol Oncol. 2006 Jun;101(3):423-8
references: 16325239
references: Gynecol Oncol. 2006 Aug;102(2):226-9
references: 16443259
references: Oncology. 2004;67(3-4):243-9
references: 15557785
references: Science. 2005 Jan 7;307(5706):58-62
references: 15637262
references: Ann Oncol. 2005 Feb;16(2):300-6
references: 15668288
references: Tumori. 2004 Nov-Dec;90(6):556-61
references: 15762356
references: Oncologist. 2005 Mar;10(3):205-14
references: 15793224
references: Gynecol Oncol. 2005 May;97(2):374-8
references: 15863132
references: Br J Cancer. 2005 Jul 11;93(1):46-53
references: 15942626
references: Gynecol Oncol. 2005 Aug;98(2):267-73
references: 15975643
references: Anticancer Res. 2005 Jul-Aug;25(4):3103-8
references: 16080573
references: Clin Cancer Res. 2005 Aug 15;11(16):5912-9
references: 16115933
references: Oncology. 2005;69(4):348-53
references: 16293974
references: Cancer Invest. 2005;23(8):665-70
references: 16377584
references: Gynecol Oncol. 2006 Feb;100(2):318-23
references: 16239023
references: Int J Oncol. 1999 Dec;15(6):1233-8
references: 10568833
references: Am J Clin Oncol. 2000 Jun;23(3):297-300
references: 10857898
references: J Clin Oncol. 2000 Sep;18(17):3093-100
references: 10963637
references: Gynecol Oncol. 2000 Sep;78(3 Pt 1):369-72
references: 10985896
references: Gynecol Oncol. 2001 May;81(2):206-12
references: 11330951
references: J Clin Oncol. 2001 Jul 15;19(14):3312-22
references: 11454878
references: Gynecol Oncol. 2001 Aug;82(2):323-8
references: 11531287
references: Clin Cancer Res. 2001 Oct;7(10):3040-6
references: 11595693
references: Am J Clin Dermatol. 2000 Jul-Aug;1(4):225-34
references: 11702367
references: Drug Saf. 2001;24(12):903-20
references: 11735647
references: Gynecol Oncol. 2002 Apr;85(1):136-9
references: 11925133
references: Br J Cancer. 2002 May 6;86(9):1379-84
references: 11986767
references: Eur J Cancer. 2002 Oct;38(15):1992-7
references: 12376203
references: J Clin Oncol. 1997 Mar;15(3):987-93
references: 9060537